Basic and translational research: from molecule,to mouse,to man

1 Karp JE McCaffrey RP . New avenues of translational research in leukemia and lymphoma: outgrowth of a leukemia Society of America-National Cancer Institute Workshop J Natl Cancer Inst 1994; 86:1196–1201.

2 Chabner BA Boral AL Multani P . Translational research: walking the bridge between idea and cure-seventeenth bruce F. Cain memorial award lecture. Cancer Res 1998; 58:4211–4216.

3 Dische S Saunders M . Translational research-a new entity? Acta Oncol 2001; 40:995–999.

4 Feldman AM Koch WJ Force TL . Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences. Clin Pharmacol Ther 2007; 81:887–892.

5 Hoyte L Kaus J Buchan AM . Lost in translation: taking neuroprotection from animal models to clinical trials. Exp Neurol 2004; 188:200–204.

6 Kieburtz K Olanow CW . Translational experimental therapeutics: the translation of laboratory-based discovery into disease-related therapy. Mt Sinai J Med 2007; 74:7–14.

7 Cripe TP Thomson B Boat TF Williams DA . Promoting translational research in academic health centers: navigating the roadmap. Acad Med 2000; 80:1012–1018.

8 Wehling M . Translational medicine: can it really facilitate the transition of research from bench to beside. Eur J Clin Pharmacol 2006; 62:91–95.

9 Filippatos GS Anker SD Kremastinos DT . Pathophysiology of peripheral muscle wasting in cardiac cachexia. Curr Opin Clin Nutr Metab Care 2005; 8:249–254.

10 Boddaert MS Gerritsen WR Pinedo HM . On our way to targeted therapy for cachexia in cancer? Curr Opin Oncol 2006; 18:335–340.

11 Lang CH Frost RA Vary TC . Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab 2007; 293:E453–E459.

12 Dudgeon WD Phillips KD Carson JA Brewer RB Durstine JL Hand GA . Counteracting muscle wasting in HIV-infected individuals. HIV Med 2006; 7:299–310.

13 Anker SD Ponikowski P Varney S Chua TP Clark AL Webb-Peploe KM Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349:1050–1053.

14 Hasselgren PO Fischer JE . Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001; 233:9–17.

15 Mitch WE Goldberg AL . Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335:1897–1905.

16 Glass DJ . Molecular mechanisms modulating muscle mass. Trends Mol Med 2003; 9:344–350.

17 Lecker SH Solomon V Mitch WE Goldberg AL . Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states J Nutr 1999; 129 (Suppl):227S–237S.

18 Attaix D Ventadour S Codran A Bechet D Taillandier D Combaret L . The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005; 41:173–186.

19 Bodine SC Latres E Baumhueter S Lai VKM Nunez L Clarke BA Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704–1708.

20 Kedar V McDonough H Arya R Li HH Rockman HA Patterson C . Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci U S A 2004; 101:18135–18140.

21 Li YP Chen Y John J Moylan J Jin B Mann DL Reid MB . TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005; 19:362–370.

22 Li YP Chen Y Li AS Reid MB . Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003; 285:C806–C812.

23 Adams V Linke A Wisloff U Doring C Erbs S Krankel N Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiov Res 2007; 73:120–129.

24 Adams V Mangner N Gasch A Krohne C Gielen S Hirner S Induction of MuRF1 is essential for TNF-[alpha]-induced loss of muscle function in mice. J Mol Biol 2008; 384:48–59.

25 Sacheck JM Ohtsuka A McLary SC Goldberg AL . IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287:E591–E601.

26 Sandri M Sandri C Gilbert A Skurk C Calabria E Picard A FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399–412.

27 Skurk C Izumiya Y Maatz H Razeghi P Shiojima I Sandri M The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005; 280:20814–20823.

28 Kisselev AF Goldberg AL . Proteasome inhibitors: from research tools to drug candidates. Chemi Biol 2001; 8:739–758.

29 Lee DH Goldberg AL . Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998; 8:397–403.

30 Adams J . Development of the proteasome inhibitor PS-341. Oncologist 2002; 7:9–16.

31 Beehler BC Sleph PG Benmassaoud L Grover GJ . Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Exp Biol Med 2006; 231:335–341.

32 Supinski GS Vanags J Callahan LA . Effect of proteasome inhibitors on endotoxin induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 2009; 296:L994–L1001.

33 Schuelke M Wagner KR Stolz LE Hubner C Riebel T Komen W Myostatin mutation associated with gross muscle hypertrophy in a child. New Engl J Med 2004; 350:2682–2688.

34 McPherron AC Lawler AM Lee SJ . Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature 1997; 387:83–90.

35 Langley B Thomas M Bishop A Sharma M Gilmour S Kambadur R . Myostatin inhibits myoblast differentiation by down-regulating myoD expression. J Biol Chem 2002; 277:49831–49840.

36 Thomas M Langley B Berry C Sharma M Kirk S Bass J Kambadur R . Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 2000; 275:40235–40243.

37 Zimmers TA Davies MV Koniaris LG Haynes P Esquela AF Tomkinson KN Induction of cachexia in mice by systemically administered myostatin. Science 2002; 296:1486–1488.

38 Liu CM Yang Z Liu CW Wang R Tien P Dale R Sun LQ . Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 2007; 15:155–160.

39 Lenk K Schur R Linke A Erbs S Matsumoto Y Adams V Schuler G . Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 2009; 11:342–348.

40 Bogdanovich S Krag TOB Barton ER Morris LD Whittemore LA Ahima RS Khurana TS . Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420:418–421.

41 McFarlane C Sharma M Kambadur R . Myostatin is a procachectic growth factor during postnatal myogenesis. Curr Opin Clin Nutr Metab Care 2008; 11:422–427.

42 Tsuchida K . Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 2008; 11:487–494.

43 Bogdanovich S Perkins KJ Krag TOB Whittemore LA Khurana TS . Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 2005; 19:543–549.

44 Wagner KR Fleckenstein JL Amato AA Barohn JR Bushby K Escolar DM A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63:561–571.

45 Muller HJ . The remaking of chromosomes. The Collecting Net-Woods Hole 1938; 13:181–198.

46 McClintock B . The stability of broken ends of chromosomes in Zea mays. Genetics 1941; 26:234–282.

47 Blackburn EH . Switching and signaling at the telomere. Cell 2001; 106:661–673.

48 Makarov VL Hirose Y Langmore JP . Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997; 88:657–666.

49 DeBoeck G Forsyth RG Praet M Hogendoorn PC . Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J Pathol 2009; 217:327–344.

50 Yang O . Cellular senescence, telomere recombination and maintenance. Cytogenet Genome Res 2008; 122:211–218.

51 Cawthon RM Smith KR O'Brien E Sivatchenko A Kerber RA . Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003; 361:393–395.

52 Greider CW Blackburn EH . Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell 1985; 43:405–413.

53 Kim NW Piatyszek MA Prowse KR Harley CB West MD Ho PL Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011–2015.

54 Shay JW Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787–791.

55 Minamino T Miyauchi H Yoshida T Ishida Y Yoshida H Komuro I . Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105:1541–1544.

56 Matsumoto Y Adams V Walther C Kleinecke C Brugger P Linke A Reduced number and function of endothelial progenitor cells in patients with aortic valve stenosis: a novel concept for valvular endothelial cell repair. Eur Heart J 2009; 30:346–355.

57 Voghel G Thorin-Trescases N Farhat N Mamarbachi AM Villeneuve L Fortier A Chronic treatment with N-acetyl-cystein delays cellular senescence in endothelial cells isolated from a subgroup of atherosclerotic patients. Mech Ageing Develop 2008; 129:261–270.

58 Mahmoudi M Gorenne I Mercer J Figg N Littlewood T Bennett M . Statins use a novel nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repairin vascular smooth muscle cells Cir Res 2008; 103:717–725.

59 Spyridopoulos I Haendeler J Urbich C Brummendorf TH Oh H Schneider MD Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110:3136–3142.

60 Werner C Hanhoun M Widmann T Kazakov A Semenov A Poss J Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol 2008; 52:470–482.

61 Hanahan D Weinberg RA . The hallmarks of cancer. Cell 2000; 100:57–70.

62 Bodnar AG Ouellette M Frolkis M Holt SE Chiu CP Morin GB Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349–352.

63 Hahn WC Counter CM Lundberg AS Beijersbergen RL Brooks MW Weinberg RA . Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464–468.

64 Dunham MA Neumann AA Fasching CL Reddel RR . Telomere maintenance by recombination in human cells. Nat Genet 2000; 26:447–450.

65 Harley CB . Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8:167–179.

66 Kelland LR . Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur J Cancer 2005; 41:971–979.

67 Asai A Oshima Y Yamamoto Y Uochi TA Kusaka H Akinaga S A novel telomerase template antagonist (GRN 163) as a potential anticancer agent. Cancer Res 2003; 63:3931–3939.

68 Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281–297.

69 Berezikov E Guryev V van de Belt J Wienholds E Plasterk RH Cuppen E . Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120:21–24.

70 Lewis BP Burge CB Bartel DP . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are MicroRNA targets. Cell 2005; 120:15–20.

71 Ikeda S Kong SW Lu J Bisping E Zhang H Allen PD Altered microRNA expression in human heart disease. Physiol Genomics 2007; 31:367–373.

72 Sayed D Hong C Chen IY Lypowy J Abdellatif M . MicroRNAs play an essential role in the development of cardiac hypertrophy. Cir Res 2007; 100:416–424.

73 Tatsuguchi M Seok HY Callis TE Thomson JM Chen JF Newman M Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007; 42:1137–1141.

74 Thum T Gross C Fiedler J Fischer T Kissler S Bussen M MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456:980–984.